An interventional study of NIRS Monitoring in Acute Kidney Injury (AKI) and Postnatal AKI, sponsored by NYU Langone Health. Recruiting at 1 site in United States. Open to participants aged 24 Weeks to 30 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by NYU Langone Health · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 370 studies in Acute Kidney Injury with a site in United States — 72 open to participants now, 88 under way, 9 of them phase 3. Acute Kidney Injury · United States.
Among the 370 studies in Acute Kidney Injury with a site in United States, this one is the 93rd largest by planned enrollment of the 237 interventional ones that give a count, is one of 22 that started in 2025, is one of 106 with no phase, reaches primary completion later than 46 of the 87 other live ones, and was the 350th registered.
1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.
Browse Acute Kidney Injury studies →72 of the 370 studies in Acute Kidney Injury with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
University of Minnesota · Sites in United States
Ages 30–75
University of California, San Francisco · Sites in United States
Ages 18+
Bassett Healthcare · Sites in United States
Ages 18+
Dana Fuhrman · Sites in United States
Ages up to 18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 24 Weeks to 30 Weeks · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
370 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 69 · Phase 3 29 · Phase 4 23
First in 1999; this study’s year is marked. 22 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 100 across 819 interventional studies indexed under Acute Kidney Injury.
Median enrollment 67 across the 237 interventional studies, 124 across the 131 observational. Of the 240 that completed or were terminated, 84 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
97 of 370 have an industry lead sponsor. The 10 most frequent:
NYU Langone Health is the lead sponsor of 1,431 studies on the registry; 258 are open to participants now.
Of its 235 completed or terminated interventional studies of FDA-regulated products, 197 (84%) have results posted.
NYU Langone Health has 2 studies filed under Acute Kidney Injury — fewer than ten, so there is no comparison to draw.
33 of the studies in Acute Kidney Injury with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07161843Phase 3Ebima Clifford OkundayeUse of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF) | 2026-12-30 |
| NCT05399537Phase 3Vantive Health LLCSafety Evaluation of Prismocitrate 18 in Patients Receiving CRRT | 2027-01 |
| NCT05084196Phase 3Rutgers, The State University of New JerseyMelatonin for Prevention of Kidney Injury | 2027-06-01 |
| NCT07001098Stanford UniversityAmino Acids for Cardiac Surgery Associated AKI | 2026-11 |
| NCT07016074University of MichiganInorganic Nitrate (NaNO3) Prevention of Contrast-Associated Acute Kidney Injury | 2026-11-30 |
Add all 33 to your calendar (.ics) → With an account.
Among the 370 studies in Acute Kidney Injury with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to describe the pattern of renal tissue oxygen saturation (SrSO2) using near-infrared spectroscopy (NIRS) in premature infants \<30 weeks gestational age. The secondary objective of this study is to evaluate prenatal and postnatal risk factors for acute kidney injury (AKI) in premature infants \<30 weeks gestational age. The investigators will also compare various rates of complications including death, length-of-stay, and prolonged duration of mechanical ventilation, among others.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All patients included in the study will be assigned to receive NIRS monitoring.
Device: NIRS Monitoring
The renal NIRS device is a non-invasive tool that uses near-infrared light to measure oxygen saturation various tissues. Renal NIRS sensors will be placed by 24 hours of the participants' admission.
Average NIRS Value (SrSO2)
NIRS values measured as renal tissue oxygen saturation (SrSO2); measured continuously over first 7 days of life.
Time frame: Up to Day-of-life 7
Serum Creatinine Values
Time frame: Day-of-life 1, Day-of-life 3, Day-of-life 7, Day-of-life 14
Average Urine Output
Time frame: Up to Day of NICU Discharge (Approximately Day-of-life 7; subject to large individual variations)
Length-of-Stay in NICU
Time frame: Day of NICU Discharge (Approximately Day-of-life 7; subject to large individual variations)
Duration of Non-Invasive Ventilation
Time frame: Up to Day of NICU Discharge (Approximately Day-of-life 7; subject to large individual variations)
Duration of Mechanical Ventilation
Time frame: Up to Day of NICU Discharge (Approximately Day-of-life 7; subject to large individual variations)
Plan to share: Yes — The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Requests should be directed to: Jordan.nelson@nyulangone.org. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
Access criteria: The investigator who proposed to use the data will be granted access upon reasonable request. Requests should be directed to Jordan.nelson@nyulangone.org. To gain access, data requestors will need to sign a data access agreement. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's DSSB.
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Jul 2027, 25 months after the start.
Of 251 non-industry interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 25 months is close to that.
Counting every sponsor, half of 269 studies reached it within 26 months; a quarter within 12 and three quarters within 44.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: start Nov 2025 → Jun 2025, primary completion Apr 2026 → Jul 2027 and completion Apr 2026 → Jul 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.